Patent classifications
G01N2458/00
BIOSENSOR DEVICE AND ASSEMBLY METHODS
The invention relates to a method of assembling a biosensor device comprising two or more biosensor units, wherein each unit comprises one or more biosensors comprising one or more carbon nanotubes (CNTs) coated with nucleic acid and one or more sensor molecules coupled to the nucleic acid, wherein each one of the one or more sensor molecules is capable of binding to a target molecule in a sample. Each biosensor unit is capable of detecting a different target molecule in a sample, and each unit comprises one or more biosensors each capable of detecting the same target molecule. The invention further relates to biosensor devices and methods for detecting target molecules in a sample using the same.
Antigen detection using photocleavable labels
Provided herein are methods of using photocleavable labels for multiplex and serial antigen detection. The methods comprise detecting the presence of photocleavable labels, which are conjugated through functional linkers to antigen-binding complexes, which in turn non-covalently bind to antigens. The presence of a photocleavable label is indicative of the presence of an antigen specifically or selectively bound by an antigen-binding complex. Also provided are apparatuses for using photocleavable labels for multiplex and serial antigen detection.
Method of quantifying biomarker with high sensitivity using photo-oxidation induced amplification
Disclosed is a method of quantifying a biomarker with high sensitivity using photo-oxidation induced amplification. The method includes performing an enzyme-substrate reaction of a measurement sample including an enzyme labeled on any one selected from among an antibody, an aptamer, and a nucleic acid specifically bound to the biomarker, optically measuring one or more optical properties selected from among amounts of color formation, light emission, and fluorescence of a product during a photo-oxidation induced amplification process while the product resulting from the enzyme-substrate reaction is continuously exposed to light to thus perform the photo-oxidation induced amplification process, indexing a time-varying pattern of the measured optical properties, and quantifying a concentration of the biomarker included in the measurement sample by comparing an index extracted during the indexing with an index of a reference sample.
LISTERIA-MONOCYTOGENES DETECTION METHOD
Novel means that enables detection of the monocytogenes bacterium alone distinctly from other bacteria belonging to the genus Listeria with sufficiently high accuracy is disclosed. The present inventors intensively analyzed the genome of the monocytogenes bacterium to identify two genes (the lmo0084 gene and the lmo2736 gene) as target regions with which the monocytogenes bacterium can be specifically detected distinctly from other bacteria belonging to the genus Listeria utilizing a nucleic acid amplification method. By a further intensive study of the base sequences of these two genes, primer setting regions for highly accurate, specific detection of the monocytogenes bacterium alone were identified, and preferred particular examples of PCR primer sets, LAMP primer sets, and real-time PCR primer-probe sets were established.
AMYLOID-BINDING COMPOUNDS AND METHODS OF USE THEREOF
A method of screening for amyloid-binding compounds, amyloid-binding compounds, and a method of detecting amyloid- (Abeta) plaques in a subject are disclosed. The method of screening for amyloid-binding compounds includes combining amyloid, a dye, and at least one test compound to form a sample solution; equilibrating the sample solution; measuring a fluorescence signal of the sample solution; and comparing the measured fluorescence signal of the sample to a control; wherein attenuation of the fluorescence signal, as compared to the control, indicates that one or more of the test compounds bind amyloid. The amyloid-binding compound includes a compound detected by the screening method. The method of detecting amyloid- (Abeta) plaques in a subject includes administering one or more of the amyloid-binding compounds to the subject, and detecting the compound within the subject.
TRYPTOPHAN-CONTAINING CHEMIGENETIC FLUORESCENT INDICATOR
Tryptophan-containing chemigenetic fluorescent indicators for detecting biologically-relevant analytes are described and are useful for detecting analytes in a living animal.
GENETICALLY ENCODED BIOSENSORS
The present disclosure provides, inter alia, genetically encoded recombinant peptide biosensors comprising analyte-binding framework portions and signaling portions, wherein the signaling portions are present within the framework portions at sites or amino acid positions that undergo a conformational change upon interaction of the framework portion with an analyte.
METHOD FOR THE QUANTIFICATION OF MEASLES AND RUBELLA TARGETS
Provided herein is a method for multiplexed detection of a plurality of targets, including targets associated with a measles (M) virus and a rubella (R) virus, including a M vaccine, a R vaccine, or a MR vaccine. A plurality of capture agents specific to a measles target and a rubella target are provided on a substrate, wherein the capture agents specifically bind to the measles target and the rubella target. Contacting the plurality of capture agents with a sample forms a capture agent-target complex which can be detected by a corresponding spatial pattern of capture agent-target complex.
SPECIFIC BIOMARKER SET FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER
Cells within liver tumor mass comprise a unique set of proteins/tumor antigens when compared to the normal liver tissues epithelial cells juxtaposed to the tumor. The presence of tumor antigens couples the production of auto-antibodies against these tumor antigens. The present invention relates to the identification and elucidation of a protein set that can act as a novel marker set for liver cancer diagnosis and prognosis. Specifically, it relates to a kit that enables diagnostic and prognostic measurement of auto-antibodies in serum of liver cancer patients. The present invention provides a non-invasive, specific, sensitive, and cost effective detection and quantification method by evaluating a set of validated liver cancer proteins/tumor antigens, which includes Bmi-1, VCC1, SUMO-4, RhoA, TXN, ET-1, UBE2C, HDGF2, FGF21, LECT2, SOD1, STMN4, Midkine, IL-17A, IL26, or DCP to complement the conventional diagnostic methods.
Gas-phase purification for accurate isobaric tag-based quantification
Described herein are mass spectrometry systems and methods which improve the accuracy of isobaric tag-based quantification by alleviating the pervasive problem of precursor interference and co-isolation of impurities through gas-phase purification. During the gas-phase purification, the mass-to-charge ratios of precursor ions within at least a selected range are selectively changed allowing ions having similar unmodified mass-to-charge ratios to be separated before further isolation, fragmentation or analysis.